GangaGen Achieves Initial CARB-X Milestone for Klebicin Program Targeting Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae Bacteria and Secures US$2.1 Million for Lead Optimization
(Bangalore, India/Singapore: August 10, 2023) GangaGen announced today that it has secured the second portion of its phased funding grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), the global partnership led by Boston University aimed at supporting the development of antibacterial products to diagnose, prevent and treat drug-resistant infections. The grant was awarded to GangaGen […]